REG-Mydecine Innovations Group Inc: Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

Mydecine InnovationsAnnouncement

13/10/2023 18:15

 

 

 

 

 

 

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth
Market in London, UK

 

 

VANCOUVER, BC, 13 October 2023 – Mydecine Innovations Group, Inc.
(“Mydecine” or the “Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF)
(FSE: 0NFA), a biotechnology company engineering the next wave of innovative
medications and treatment protocols to directly address mental health with a
particular emphasis on addiction and PTSD, announces that it has completed its
admission to the Access segment of the AQSE Growth Market (“AQSE”) and
that trading commenced at 8:00 A.M. GMT on Tuesday, 10 October 2023
("Admission") under the ticker "MYIG".

 

Company Highlights:

 

-      Mydecine Innovations Group Inc. is an emerging biotech and life
sciences company dedicated to developing and commercializing innovative
solutions for treating mental health problems and enhancing wellbeing.

 

-      The Companies various families of Novel 2nd generation molecules
are showing significant improvements over the first generation of psychedelic
treatments.  The Company has taken the approach that, in order to have a
truly successful drug that is accessible by all, numerous modifications need
to be made to the first generation MDMA or Psilocybin molecules, most notably
shortening the half-life while keeping the experience integrity intact.

 

-      The Company is currently working with its pre-clinical team at the
University of Alberta to work these molecules through the Investigational New
Drug enabling stage with the intent to put them into human clinical studies
expected to commence in 2024.

 

-      The Company has a comprehensive intellectual property strategy
covering novel molecules, drug formulations, delivery mechanisms, and methods
of production. The Company believes this covers all described drug development
activities in our named pipeline and clinical trials. The Company has filed
these applications both in the United States and through the Patent
Cooperation Treaty (PCT) for protection in all jurisdictions in which the
Company does business.

 

Management Commentary:

 

Josh Bartch, CEO of the Company stated, “We are incredibly excited to list
our securities for trading in the UK on the AQSE Growth Market.  We believe
Mydecine is at a pivotal phase in its development and look forward to
increased exposure to UK and European investors alike”.

 

 

 

The Company will have a dual listing with its common shares fully fungible
through a CREST Depositary Interest ("CDI"). The CDIs will carry the same ISIN
as the Common Shares listed in Canada on NEO.The issued share capital of
Mydecine comprises 45,207,458 common shares.

 

Sector Classification:

The Company is classified as a Healthcare company on the Access Segment of the
Aquis Stock Exchange.

 

This announcement, together with any documents incorporated by reference,
shall be deemed to constitute an admission document for the purposes of the
AQSE Growth Market Rules for Issuers – Access. It has not been approved or
reviewed by the Aquis Stock Exchange or the Financial Conduct Authority.

 

The Directors are of the opinion, having made due and careful enquiry, that
the working capital available to the Company is sufficient for a period of at
least twelve months following admission.

 

The Directors of Mydecine take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

Learn more at https://www.mydecine.com.

For more information, please contact:

Mydecine Innovations Group, Inc.

Media Contact    pr@mydecineinc.com

Investor Relations    investorrelations@mydecineinc.com

 

On behalf of the Board of Directors

Josh Bartch, Chief Executive Officer

contact@mydecineinc.com

 

 

AQSE Corporate Advisor

Novum Securities Limited  Tel: +44 (0)207 399 9400

David Coffman/ George Duxberry

 

 

For further information about Mydecine Innovations Group, Inc., please visit
the Company’s profile on SEDAR+ at www.sedarplus.com or the Company’s
website at www.mydecine.com.

 

About Mydecine Innovations Group Inc.

Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical
company that began operations in North America and Europe in early 2020.
Mydecine was founded to increase physicians' access to serotonin-modulating
medicine. Recent research has demonstrated the therapeutic potential of
psychedelic substances such as psilocybin and MDMA for treating intractable
conditions such as pain, anxiety, depression, addiction, and PTSD, along with
neurodegenerative disorders. Mydecine believes these compounds can be safer,
more effective, and more accessible for patients and medical professionals
through modern drug chemistry paired with artificial intelligence (AI).
Mydecine is developing innovative medications for target indications with high
mortality rates that have lacked innovation for decades and are controlled by
dominant corporations. Mydecine developed several prodrug families, beginning
with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded
trial at Johns Hopkins University. Mydecine is also developing
MYCO-006—short-acting chemical analogs derived from MDMA for treating
various conditions, including anxiety and pain. Mydecine utilises cutting-edge
artificial intelligence (AI) and pharma research infrastructure at the
University of Alberta to develop and manufacture new medications to make them
affordable and accessible to the general public upon Health Canada and FDA
approval. The Mydecine team is enthusiastic about its mission and is dedicated
to creating a positive difference in the lives of others.

 

Directors:

 

Josh Bartch, Chief Executive Officer and Chairman

 

Josh Bartch is Director, Chief Executive Officer, and Chairman of Mydecine
Innovations Group (MIG). His entrepreneurial career commenced in 2009 when he
cofounded AudioTranscriptionist.com and founded the Denver-based dispensary,
Doctors Orders. Following these ventures, Josh founded a boutique investment
firm that operated throughout the U.S. and Canadian markets. In 2014, he
co-founded Cannabase.io, the U.S.’s most significant legal and sophisticated
cannabis wholesale platform. He made successful exits from
AudioTranscriptionist.com, Doctor’s Orders, and Cannabase.io.

 

 

Robert Roscow, Chief Science Officer

 

Robert is Chief Science Officer of Mydecine bringing his diverse background in
biology, biotechnology, policy and intellectual property to innovation in the
mycology space. Robert’s substantial expertise includes genetic engineering,
molecular biology, bioinformatics, plant breeding and tissue culture,
photomicroscopy, unicellular microinjection, fish husbandry and breeding
colony maintenance and

transfection.

Following academic work studying the genetic dynamics of cellular patterning,
Robert applied his advanced knowledge to cannabis plant enhancement. He joined
ebbu in 2015, where he created IP related to the commercial optimisation of
Cannabis sativa, industrial hemp and hops, resulting in three pending US
patents.

In 2019 Rob oversaw the design, build and staffing of a plant analytical
chemistry laboratory in Ontario, Canada, for Canopy Growth Corporation where
he was Lead Director of Genetic Research. He also participated in the Colorado
Hemp Advancement & Management Plan Initiative Cannabis Industry as an industry
stakeholder in 2019.

 

Neil Stevenson-Moore, Non-Executive Director

 

Neil is an experienced executive and thought leader in the technology
community. He has a track record of driving growth, success and innovation and
has worked in both corporate and entrepreneurial environments. For the past 15
years he has founded, led, and advised companies in consumer focused and
medical tech industries including House of Kibaa, SportNinja, Farfetch and
StylePixi He has successfully raised tens of millions of dollars from private
investors, community partners, and government organisations. Neil holds a
Bachelor of International Politics from Princeton University and has
additional coaching certifications. He is fluent in French and proficient in
Spanish.

 

 

Forward-looking Information

This news release contains forward-looking information about Canadian
securities laws regarding the Company and its business. It relates to future
events or performance and reflects management’s expectations and
assumptions. Often but not always, forward-looking information can be
identified by the use of words such as “expect,” “intends,”
“anticipated,” “believes,” or variations (including negative
variations) of such words and phrases or by stating that specific actions,
events, or results “may,” "could," "would,” or “will” be taken,
occur, or be achieved.

Such forward-looking statements reflect management’s beliefs and are based
on assumptions and information currently available to the Company. Readers are
cautioned that these forward-looking statements are neither promises nor
guarantees and are subject to risks and uncertainties that may cause future
results to differ materially from those expected, including, without
limitation, risks regarding the COVID-19 pandemic, the availability and
continuity of financing, the ability of the Company to protect and enforce its
intellectual property adequately, the Company's ability to bring its products
to commercial production, the continued growth of the global adaptive pathway
medicine, natural health products, and digital health industries, and the
risks presented by the highly regulated and competitive market concerning the
development, production, sale, and use of the Company's products. Although the
Company has attempted to identify important factors that could cause actual
results to differ materially from those contained in forward-looking
information, other factors may cause effects not to be as anticipated,
estimated, or intended. There can be no assurance that such information will
be accurate, as actual results and future events could differ materially from
those anticipated. These forward-looking statements are made as of the date
hereof. The Company is not obligated to update or revise them to reflect new
events or circumstances as required under applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of the securities in any State in
which such offer, solicitation or sale would be unlawful. The securities being
offered have not been, nor will they be, registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the
United States absent registration or an applicable exemption from the
registration requirements of the United States Securities Act of 1933, as
amended, and applicable state securities laws.

 

MYDECINE INNOVATIONS GROUP, INC.
Suite 810–789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T:
604-687-2038

 3853743_0.png (https://news.cision.com/mydecine-innovations-group-inc/i/3853743-0-png,c3225468)  



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved